All News
Pregnancy in SpA Patients: Dr Rachel Tate ( @uptoTate) #ACR20
https://t.co/GPrwd9HU5W https://t.co/TbwN4dZNul
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD : Wonder if you can predict which pts you can taper off bDMARDs? Abst#1538 from Denmark showed that a neg IgM-RF (OR 0.26); low Doppler serum score for 24 jts predicted discontinuation of bDMARDs at 2yr f/u in RA pts w/ DAS28-CRP<2.6. https://t.co/6hv5M1CQwT
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @bella_mehta :Anakinra in #Stills disease - Dbl blind, placebo controlled RCT in Stills disease total 12pts, 6 placebo, 6 Rx grp. All pts reached ACR70 at wk 2 without fever and sustained it at 12 weeks. 5/6 reached ACR90
ABS#1633 https://t.co/CCL6GONnvX https://t.co/KaoXBj3Azp
Links:
Dr. John Cush RheumNow ( View Tweet)
Coal Miners and RA: Dr Janet Pope ( @Janetbirdope) reviews abstract #1462 presented at #ACR20.
https://t.co/frZ3uYNsuA https://t.co/nFHmzYA8KS
Links:
Dr. John Cush RheumNow ( View Tweet)
Revist #ACR20. The RheumNow podcast on Day 2, Part I is available for download.
https://t.co/VAPnzYtCIK https://t.co/Pm9g8S1jmn
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RichardPAConway : Dr Benard reports an SLR and meta-analysis of 27 studies comparing 2 rituximab regimes in AAV. 375mg x4 and 1000mg x2 equivalent. Remission in 91% vs 85%. Similar adverse event rates @rheumnow #ACR20 Abstr#2048 https://t.co/6fQNzqsvby
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Rheumatology reimbursement by CMS:
""If all goes well, in a few months, you will see a 16% increase in rheumatology.""
- From ACR Advocacy Updates
@RheumNow #ACR20 Abs#5M017
Dr. John Cush RheumNow ( View Tweet)
Is COVID19 infection bad for rheumatic disease patients? Dr. Jeff Curtis ( @RADoctor) reviews abstract L01 presented at #ACR20.
https://t.co/hm7geJKzNt https://t.co/gAY6k7ywLw
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/HUucJOgQgN https://t.co/xJB2zU1y2U
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush interviews Dr. Petri about the comparative value of lupus anticoagulant vs. other antiphospholipid antibody tests and their role in CVA or MI. #ACR20
https://t.co/IyeRDzw4BC https://t.co/k5LpJ8kkaz
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RHEUMarampa : Novel predictors of early mortality in a cohort of GCA pts from Portugal:
🚩Older age at dx
🚩Tongue claudication
🚩Prior tx w/ anticoag
BP treatment at dx - predictor of early survival. @RheumNow #ACR20 abs1935 https://t.co/vCi2gMCmKE https://t.co/HuTv1p8Yua
Links:
Dr. John Cush RheumNow ( View Tweet)
The Lungs: The Alpha and Omega of RA with Dr. Jonathan Kay #ACR20
https://t.co/zhCRaeKOfu https://t.co/zVwgzu9ULs
Links:
Dr. John Cush RheumNow ( View Tweet)
Blood Brain Barrier Leakage in SLE: Dr. Janet Pope ( @Janetbirdope) reviews abstract #1508 from #ACR20 meeting.
https://t.co/JSHyuGtv3O https://t.co/pGaskVnCfi
Links:
Dr. John Cush RheumNow ( View Tweet)
Revisit Day 1 of #ACR20 through the RheumNow podcast. Follow the link below or find us on Apple/Android podcasts.
https://t.co/Hj4uIYzFuL https://t.co/WXecOcVDQR
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recs for RA: Use MTX, starting oral but remember MTX tricks to maximize success. Folic acid, split dosing, SubQ all keys per Dr. O'Dell to maximize @RheumNow. https://t.co/OEAGi0bSZH https://t.co/aHsHF1Vm4l
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recs for RA: on max tolerated MTX - add bio or tsDMARD conditional recommendation over triple therapy (MTX, HCQ, SSZ). @RheumNow. https://t.co/uff7Vj0iKA https://t.co/Tquq7FN86y
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recs for RA: discontinue MTX over biologic or tsDMARD in "patients that strongly want to discontinue", conditional recommendation supported by SEAM-RA Abst#939 @RheumNow https://t.co/2Ozvkq4Rjo https://t.co/xlbKAItFzN
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out our latest article from Dr. Janet Pope ( @Janetbirdope)
How are RA patients doing using telemedicine/virtual care?
https://t.co/YffT28OwgY https://t.co/xnAe3lKL8W
Links:
Dr. John Cush RheumNow ( View Tweet)
(if this is true) Shame on @expressScripts and forcing money driven biologic changes (from secukinumab to ixekizumab) upon patients and doctors. This is soooo wrong! https://t.co/DYKSItCbYL
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrMiniDey : Study on #telehealth in #rheumatology patients in the US finds those with #comorbidities and high disease activity are most likely to take up remote consults.
Abs#1962 #ACR20 @RheumNow
https://t.co/8USU39mTPk https://t.co/ioT1b1x4IO
Links:
Dr. John Cush RheumNow ( View Tweet)
